StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) PT Lowered to $200 at Piper Sandler
August 8, 2024 7:41 AM
Piper Sandler analyst Biren Amin lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $200.00 (from $205.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
August 8, 2024 8:18 AM